ライフサイエンスコーパス: MCS

1 MCS caregiving affects QoL for both patients and caregiv

2 MCS centers have improved patient management by introduc

3 MCS recipients are debilitated and have some immunologic

4 MCS-based solution shifts production from stationary to

5 MCSs are formed by tether proteins that bridge the oppos

6 MCSs are typically maintained through dynamic protein-pr

7 MCSs between the ER and PM, the ER/PM junctions, are the

8 ce interaction-beta=0.22; 95%CI:-0.62,1.05) (MCS x race interaction-beta=0.18; 95%CI:-0.08,0.44).

9 The sample included 30 MCS patients and their caregivers.

10 0.3 to 5.4; P = .08), no change in the SF-36 MCS score at 3 weeks (mean, 2.2; 95% CI, -0.4 to 4.8; P

11 7; P = .02) greater improvement in the SF-36 MCS score at 52 weeks.

12 rl3, which corresponds to the NPRL3 intron 7 MCS-R1 enhancer of jawed vertebrates.

13 ited time to engage in decision-making about MCS implantation, people entered MCS caregiving relation

14 lysosome to ER cholesterol transport across MCS.

15 oon pump versus other forms of MCS (advanced MCS) had lower Sequential Organ Failure Assessment score

16 ng centers and at centers with more advanced MCS use.

17 ver, data describing clinical outcomes after MCS in this population are limited.

18 All MCS devices increased forward blood flow and arterial pr

19 sustained virological response patients all MCS symptoms persistently disappeared (36 patients, 57%)

20 ls, leading to reduced infection rates among MCS recipients.

21 lower PCS scores (48.0 v 52.8; P < .001) and MCS scores (45.8 v 48.9; P = .002) when compared with po

22 ction, beta = 0.22, 95% CI: -0.62, 1.05, and MCS x race interaction, beta = 0.18; 95% CI: -0.08, 0.44

23 lation mean for both PCS (45.6 +/- 10.4) and MCS (47.3 +/- 11.5) but increased to just above the nati

24 The median SF-12 PCS was 46.6 and MCS was 53.2.

25 of follow-up for both PCS (50.7 +/- 9.6) and MCS (50.1 +/- 10.0).

26 dialysis normative scores were PCS=37.8 and MCS=50.9 (scored on a T-score metric); and KSS=73.0, BKD

27 itivity and specificity in the benchmark and MCS population, PCI offers a reliable, independently val

28 e of overall complications between FLACS and MCS (RR, 2.15; 95% CI, 0.74 to 6.23; P = 0.16); however,

29 Studies containing both FLACS and MCS arms that reported on relevant efficacy and/or safet

30 lly significant difference between FLACS and MCS for total surgery time (WMD, 1.25; 95% CI, -0.08 to

31 icant differences detected between FLACS and MCS in terms of patient-important visual and refractive

32 nt difference was detected between FLACS and MCS in uncorrected distance visual acuity (WMD, -0.02; 9

33 Significant improvements in PCS and MCS scores from baseline to 24-month follow-up were obse

34 alyses revealed that improvements in PCS and MCS scores were primarily a function of being off-treatm

35 ation, whereas in the lower cluster, PCS and MCS scores were significantly lower than in the general

36 identified for the time profiles of PCS and MCS.

37 ll eyes, our results support that ReLACS and MCS yield similar outcomes.

38 understanding of the linkage between EMs and MCSs.

39 ng antiviral (DAA) therapy in HCV-associated MCS (HCV-MCS) is largely unknown.

40 At MCS, specific proteins tether the organelles in close pr

41 ing domains found exclusively in proteins at MCS.

42 oss follow-up, mean improvements in the BDI, MCS and PCS scores, were 1.9 (95%CI, 1.0-2.8), 3.1 (95%C

43 with the highest inhibition was found to be MCS, with an IC50 value of 0.29muM.

44 groups for those who required biventricular MCS.

45 luated efficacy and safety of early combined MCS (Impella microaxial pump + venoarterial extracorpore

46 mine factors for decision-making in combined MCS.

47 MO were combined early (duration of combined MCS: median 94 hours; interquartile range, 49-150 hours)

48 tory CS from our registry requiring combined MCS.

49 We compute MCS solution-sets for a non-native product indigoidine,

50 We fed mice custom MCS and MCD formulas containing 4 different carbohydrate

51 atients, 57%); in only two (3%) did definite MCS persist.

52 gh most people adjusted to the task demands, MCS caregiving had a significant impact, both positive a

53 In the present report we describe MCSs obtained from post-diagnosed, pre-treated patient-d

54 ulted in a sensitivity of 94.7% in detecting MCS and allowed the identification of a number of unresp

55 PDZD8 is a shared component of two distinct MCSs and suggest a role for SMP-mediated lipid transport

56 port proteins (Ltc/Lam) localized at diverse MCSs.

57 ndpoint was survival at 1 year after durable MCS implantation.

58 a highlight concerns with the use of durable MCS for patients with ACM.

59 h DCM or nonamyloid RCM who received durable MCS, those with ACM experienced the highest use of biven

60 The outcome in patients receiving durable MCS after ECLS remains limited, yet preoperative factors

61 The Durable MCS after ECLS registry is a multicenter retrospective s

62 A total of 531 durable MCSs after ECLS were implanted during this period.

63 Early MCS escalation stabilized patients rapidly, reducing num

64 e components localize to an ER-late endosome MCS.

65 At these ER-late endosome MCSs, mitochondria are also recruited to form a three-wa

66 aking about MCS implantation, people entered MCS caregiving relationships naive to its full demands.

67 v2.1 localization and the induction of PM:ER MCS are accompanied by increased mitotic Kv2.1 phosphory

68 The M phase clustering of Kv2.1 at PM:ER MCS in COS-1 cells requires the same C-terminal targetin

69 ession of Kv2.1 induces more exuberant PM:ER MCS in neurons and in certain heterologous cell types.

70 smic reticulum membrane contact sites (PM:ER MCS), and overexpression of Kv2.1 induces more exuberant

71 fic clusters of Kv2.1 are localized to PM:ER MCS, and M phase clustering of Kv2.1 induces more extens

72 tering of Kv2.1 induces more extensive PM:ER MCS.

73 to form hotspots for membrane dynamics at ER MCSs that can persist through sequential events.

74 sion machinery, Mitofusins, accumulate at ER MCSs where fusion occurs.

75 Indeed, we discover that ER MCSs define the interface between polarized and depolari

76 CS cells developed increased climbing fiber (MCS) or parallel fiber (ZCS) input during visual stimula

77 hese, 1064 (73.9%) had at least one code for MCS.

78 Indeed, functions for MCSs in intracellular signalling (particularly calcium s

79 We found MCS produces significant changes in offspring gene expre

80 p and both the MC-HCV (P = 0.009) and MC-HCV+MCS-HCV (P = 0.014) groups.

81 HCV-MCS was defined by circulating cryoglobulin associated w

82 tes for sofosbuvir-based DAA regimens in HCV-MCS were 83%, significantly higher than historical contr

83 ral (DAA) therapy in HCV-associated MCS (HCV-MCS) is largely unknown.

84 ors studied case series of patients with HCV-MCS who were treated with sofosbuvir-based regimens and

85 High MCS utilizing hospitals were larger ( P<0.001).

86 In addition to maintaining cell homeostasis, MCS formation recently emerged as a mechanism by which i

87 e 1980s (e.g., 0.229 [95% CI 0.219-0.240] in MCS males; 0.071 [0.065-0.078] in NSHD males).

88 There were 6070 families in GUI and 7768 in MCS.

89 ns in infection prevention and management in MCS patients.

90 ing the existence of redundant mechanisms in MCS formation.

91 A surprising new function for OSBP in MCS dynamics has now been uncovered in a recent study by

92 The clinical-immunological response in MCS-HCV correlated with the virological one.

93 lowing R peak was significantly shortened in MCS when the auditory rule was violated.

94 Interest in MCSs has grown dramatically in the past decade as it is

95 d not suppress the formation of ER-inclusion MCS, suggesting the existence of redundant mechanisms in

96 contribute to the formation of ER-inclusion MCS.

97 , relative humidity, and VWS, which increase MCSs' lifetime by 3-30 h, 3-27 h, and 3-30 h per 1sigma

98 We find that intense MCS frequency is only weakly related to the multidecadal

99 ncrease in the frequency of the most intense MCSs.

100 Dry soil patterns intensify MCSs through a combination of convergence, increased ins

101 th anxiety, it explained 24% of interpatient MCS variability.

102 y and particularly on days with long-lasting MCSs, accounts for the changes in the precipitation prod

103 ased frequency and intensity of long-lasting MCSs.

104 With learning, MCS and ZCS cells developed increased climbing fiber (MC

105 ess severity was similar at high- versus low-MCS utilizing centers and at centers with more advanced

106 were not different between higher and lower MCS-utilizing hospitals.

107 1, P = 0.031) and more commonly reduced MAE (MCS: 0.60 +/- 0.02 diopters (D) vs ReLACS: 0.54 +/- 0.02

108 % CI: 1.15-2.74, P = 0.01); 2) reducing MAE (MCS: 0.73 +/- 0.3 D vs ReLACS: 0.60 +/- 0.27 D, P = 0.04

109 t of drier soils on convection within mature MCSs.

110 f hospitalizations for MI with CS using MCS (MCS ratio) and in-hospital mortality were evaluated.

111 no significant difference in change of mean MCS scores (intervention group mean at baseline, 49.1; a

112 (CI): 0.40, 1.49) and possibly better median MCS (beta = 0.46, 95% CI: -0.01, 0.94).

113 95%CI: 0.40,1.49) and possibly better median MCS (beta=0.46; 95%CI:-0.01,0.94).

114 tifs may be a common feature of VAP-mediated MCS formation.

115 mes included mean physical (PCS) and mental (MCS) health QOL composite scores and reporting long-term

116 expanded population of lysosome-mitochondria MCS in cells depleted of NPC1 or Gramd1b that is depende

117 ter increase in mean improvement in modified MCS from baseline than placebo (difference from placebo,

118 increase in the mean improvement in modified MCS from baseline to week 12.

119 n mean improvement from baseline in modified MCS of 0.43 points more than placebo (90% confidence int

120 Moreover, MCS-01 altered the macrophage phenotype, promoting class

121 PCS but not MCS scores were worse for AYA patients diagnosed with ca

122 The probability of IABP and O-MCS use varied across hospitals, and the use of O-MCS wa

123 tal-level variation in the use of IABP and O-MCS were evaluated.

124 ly, and 2747 (3.6%) received both IABP and O-MCS.

125 over time without a concurrent increase in O-MCS use.

126 The probability of O-MCS use was <5% for half of hospitals and >20% in less t

127 e of 0.3% per quarter, whereas the rate of O-MCS use was unchanged over the study period.

128 se varied across hospitals, and the use of O-MCS was clustered at a small number of hospitals.

129 ) received IABP only, 2711 (3.5%) received O-MCS only, and 2747 (3.6%) received both IABP and O-MCS.

130 c shock received an IABP and 6.7% received O-MCS.

131 and other mechanical circulatory support (O-MCS) devices in patients undergoing percutaneous coronar

132 Eighty-five percent (2808/3301) of MCS use was intra-aortic balloon pump.

133 s use increased over time, reaching 31.9% of MCS in 2016.

134 The early and consequent combination of MCS by Impella microaxial pumps and VA-ECMO enables stab

135 al membrane oxygenation, or a combination of MCS device use), or medical therapy only.

136 embrane protein VAP is a common component of MCS involved in both tethering and lipid transfer by bin

137 The predominant form of MCS use is intra-aortic balloon pump.

138 traaortic balloon pump versus other forms of MCS (advanced MCS) had lower Sequential Organ Failure As

139 monary flows remained high with all forms of MCS.

140 =0.007) and lactate levels after 12 hours of MCS (hazard ratio, 1.28 [95% CI, 1.09-1.51]; P=0.002) in

141 re is limited understanding of the impact of MCS caregiving on patients and caregivers.

142 d to persistent resolution or improvement of MCS, strongly suggesting the need for a next generation

143 ensure that physical and emotional needs of MCS patients and caregivers are identified and addressed

144 However, preloading of MCS columns with dissolved Mn(II) led to suppressed reac

145 e median (interquartile range) proportion of MCS use among admissions for MI with CS was 33.3% (0.0%-

146 Caregiving impacts QoL of MCS patients and their caregivers long term.

147 lity of supportive networks influence QoL of MCS patients and their caregivers.

148 d outcomes were compared across quartiles of MCS usage.

149 tality was not different across quartiles of MCS use (Q4 versus Q1; odds ratio, 0.95; 95% CI, 0.77-1.

150 here was significant variation in receipt of MCS at different hospitals (median odds ratio of receivi

151 are needed to define the appropriate role of MCS in patients undergoing PCI.

152 Wide variation exists in hospital use of MCS for MI with CS, unexplained by patient characteristi

153 Despite the additional computation of MCSs, AILP achieved significant time reduction in comput

154 o aid the visualization and interrogation of MCSs in both fixed and living cells.

155 These findings reveal the central role of MCSs in determining efficiency and fidelity of cell sign

156 explains up to 24% of the total variance of MCSs' lifetime during the decay phase.

157 xplain up to 20-22% of the total variance of MCSs' lifetime over equatorial South America compared wi

158 n Ocean can explain 20% of total variance of MCSs' lifetime over South Asia because such MCSs form an

159 disease severity, survival was favorable (on MCS 61%, 30 days 49%, 6 months 40%).

160 The effect of aerosols on MCSs' lifetime varies between different continents.

161 f local regularities in either the VS/UWS or MCS patients.

162 stigate the impact of ER-endocytic organelle MCS on cholesterol transport.

163 1 (NPC1) in tethering ER-endocytic organelle MCS where it interacts with the ER-localised sterol tran

164 ER peaks were also present at other MCS, implying that membrane curvature enforcement may be

165 eather in the Sahel and potentially in other MCS hotspot regions of the world.

166 ignificant difference in favor of FLACS over MCS for effective phacoemulsification time (WMD, -3.03;

167 Mean PCS, MCS, and PHQ-9 scores were relatively stable over a medi

168 o be considered when choosing a percutaneous MCS device for AMI-VSD.

169 d effects of different types of percutaneous MCS (including intra-aortic balloon pumping, Impella, Ta

170 Although no form of percutaneous MCS normalized hemodynamics in AMI-VSD, pulmonary capill

171 ER-PM MCS are particularly abundant in Saccharomyces cerevisia

172 is of soil moisture feedbacks on propagating MCSs anywhere in the world and show a strong positive im

173 ity to assess the resistance profile of PTPD MCSs and two-dimensional (2D) monolayer cultures of the

174 nt hospitals (median odds ratio of receiving MCS at 2 random hospitals: 1.58; 95% CI, 1.45-1.70).

175 nt may be a widespread mechanism to regulate MCS function.

176 remarkably rapid intensification of Sahelian MCSs since the 1980s sheds new light on the response of

177 rming intensifies convection within Sahelian MCSs through increased wind shear and changes to the Sah

178 ss-linked with divalent cationic CaCl2 salt (MCS), and the third group consisted of control microcaps

179 pipemidic acid (PIP), in MnO(2)-coated sand (MCS) columns is altered by the presence of dissolved Mn(

180 52.8; P < .001) and mental component scale (MCS) scores (42.9 v 48.9; P < .001) when compared with p

181 or the mental and physical composite scores (MCS and PCS) and for the 8 dimensions of the short-form

182 utpatients with modified Mayo Clinic scores (MCSs) (stool frequency, rectal bleeding, and endoscopy f

183 these metrics, we take the minimal cut set (MCS) approach that predicts metabolic reactions for elim

184 on deletion sets represent minimal cut sets (MCSs).

185 Unique multicore-shell (MCS) structure of the electrospun composite fibers was o

186 Monte Carlo simulations (MCS) were performed for models with one susceptible bact

187 dsRNA produced by the multiple cloning site (MCS) of L4440, which shares complementary sequences with

188 s include acting as a membrane contact site (MCS) tether as well as a lipid antiporter.

189 Membrane contact sites (MCS) are zones of contact between the membranes of two o

190 Membrane contact sites (MCS) between organelles are proposed as nexuses for the

191 Membrane contact sites (MCS) between the endoplasmic reticulum (ER) and the plas

192 Membrane contact sites (MCS), microdomains of close membrane apposition, are gai

193 Membrane contact sites (MCSs) are specialized subcellular compartments formed by

194 Recently, membrane contact sites (MCSs) between the endoplasmic reticulum (ER) and endosom

195 Membrane contact sites (MCSs) function to facilitate the formation of membrane d

196 nelles take place at membrane contact sites (MCSs).

197 ER)-vacuole/lysosome membrane contact sites (MCSs).

198 ly coordinated at ER membrane contact sites (MCSs).

199 acts, often called 'membrane contact sites' (MCSs).

200 ensional (3D) multicellular tumor spheroids (MCSs) to assess drug resistance; however, a unified syst

201 as multiple, single, or zero complex spike (MCS, SCS, ZCS) cells.

202 ndole-carboxamide type mast cell stabilizer, MCS-01, which proved to be an effective mast cell degran

203 tate (VS/UWS), 36 minimally-conscious state (MCS) and 11 severe disability.

204 rentiation of the minimally conscious state (MCS) and the unresponsive wakefulness syndrome (UWS) is

205 drome (VS/UWS) or minimally conscious state (MCS).

206 /UWS; n = 70) and minimally conscious state (MCS; n = 57) were presented with the local-global audito

207 patients (38 in a minimally conscious state [MCS] and 43 in a vegetative state [VS]).

208 me, VS/UWS, and 7 minimally conscious state, MCS) and compared these properties with those of healthy

209 maximum clustering set-proportion statistic (MCS-P) are used to select appropriate parameters without

210 The Millennium Cohort Study (MCS) is a birth cohort study in the UK following up chil

211 , and the 2000-2002 Millennium Cohort Study (MCS) to analyze how this association has changed over ti

212 PAC; 7-18), or 2001 Millennium Cohort Study (MCS; 3-11).

213 [GUI]) and the UK (Millennium Cohort Study [MCS]).

214 MCSs' lifetime over South Asia because such MCSs form and develop over the ocean.

215 the BDI and SF-36 Mental Component Summary (MCS) and Physical Component Summary (PCS) scores, respec

216 Summary (PCS) and Mental Component Summary (MCS) from the Short Form Health Survey.

217 ischarge using the Mental Component Summary (MCS) of the 36-Item Short-Form Health Survey (SF-36 [ran

218 Summary (PCS) and Mental Component Summary (MCS) of the Veterans RAND 12-Item Health Survey, the Pat

219 Summary (PCS) and Mental Component Summary (MCS) scores (0-100 scale; higher scores better).

220 Summary (PCS) and Mental Component Summary (MCS), and the KDQOL-36's BKD, SPKD, and EKD scales for t

221 perinatal maternal choline supplementation (MCS) in a mouse model of Down syndrome and Alzheimer's d

222 e effects of mechanical circulatory support (MCS) are promising, although many aspects are elusive.

223 revention in mechanical circulatory support (MCS) device recipients.

224 Mechanical circulatory support (MCS) devices are increasingly used to provide hemodynami

225 Temporary mechanical circulatory support (MCS) devices provide hemodynamic assistance for shock re

226 percutaneous mechanical circulatory support (MCS) for AMI-VSD is unknown.

227 , nondurable mechanical circulatory support (MCS) for myocardial infarction (MI) complicated by cardi

228 approved for mechanical circulatory support (MCS) in 2008, but large-scale, real-world data on its us

229 and durable mechanical circulatory support (MCS) may be a consideration.

230 atients with mechanical circulatory support (MCS) require the identification of a caregiver to assist

231 can provide mechanical circulatory support (MCS) to patients with acute hemodynamic compromise and c

232 (FLACS) relative to manual cataract surgery (MCS).

233 Miles-Carpenter syndrome (MCS) was described in 1991 as an XLID syndrome with fing

234 on cause of mixed cryoglobulinemia syndrome (MCS).

235 onging to the following groups: MC syndrome (MCS)-HCV (121 patients with symptomatic MC), MC-HCV (132

236 well-developed mesoscale convective system (MCS) was studied using both satellite observations and c

237 ltiphase flows inside microcapillay systems (MCS).

238 lant durable mechanical circulatory systems (MCSs) in patients on extracorporeal life support (ECLS)

239 e dominated by mesoscale convective systems (MCSs), the largest type of convective storm, with increa

240 intense storms-mesoscale convective systems (MCSs)-poses a particular challenge, because they organiz

241 tely triggered mesoscale convective systems (MCSs).

242 he lifetime of mesoscale convective systems (MCSs).

243 The most common temporary MCS devices were intraaortic balloon pumps (72%), Impell

244 While hospital-level variation in temporary MCS device selection is not explained by differences in

245 re is wide variation in the use of temporary MCS among patients with shock in tertiary CICUs.

246 s with CS or mixed shock, 34% used temporary MCS during the CICU stay with substantial variation betw

247 Of the 270 admissions using temporary MCS, 33% had acute myocardial infarction-related cardiog

248 ing overall practice patterns with temporary MCS in cardiac intensive care units.

249 ng hospital costs associated with short-term MCS.

250 We show that artificially tethering MCS rescues the cholesterol accumulation that characteri

251 unded and unwounded mouse skin revealed that MCS-01 primarily altered the gene expression of mast cel

252 nalysis of trends across Africa reveals that MCS intensification is limited to a narrow band south of

253 s treated with MCS-01 or placebo showed that MCS-01 significantly modulated the mRNA and microRNA pro

254 We show that MCSs provide a robust and reliable in vitro model to eva

255 Our results show that MCSs' lifetime increases by 3-24 h when vertical wind sh

256 Long-term support by the MCS clinical team can help ensure that physical and emot

257 mulate a natural mutation, which deletes the MCS-R2 alpha-globin enhancer and causes alpha-thalassemi

258 Children recruited from the MCS have been followed up over six recruitment sweeps to

259 as more than halved for children born in the MCS cohort (-0.14, 95% CI: -0.22, -0.06).

260 six-item psychological distress scale in the MCS cohort when children were 7 years old.

261 t p=0.435 in the GUI cohort and 0.470 in the MCS cohort).

262 0.18 SMFQ points (0.01-0.36; p=0.041) in the MCS cohort.

263 rs in the GUI cohort and age 14 years in the MCS cohort.

264 hift of the cardiac cycle exclusively in the MCS group.

265 Moreover, the MCS membrane (at ~200 degrees C), as a lithium ion batte

266 maintains similar performance to that of the MCS-P in spatial datasets with homogeneous clusters.

267 Based on the MCS-P, we proposed a new indicator, the maximum clusteri

268 ibuted remarkable thermal stabilities to the MCS membrane.

269 er performance than those selected using the MCS-P; moreover, higher heterogeneity led to a larger ad

270 lly in complex practical datasets, while the MCS-P may have unsatisfactory performance in spatial dat

271 consistent with that of the variation of the MCSs' ice water content (IWC) with aerosols, which accou

272 nd 34%, respectively, of the variance of the MCSs' lifetime.

273 superior to MCS for reducing surgical time (MCS: 7.7 +/- 0.1 min vs ReLACS: 6.8 +/- 0.1 min, P < 0.0

274 ore pronounced benefit of ReLACS compared to MCS when treating more difficult eyes.

275 activity was decreased in VS/UWS compared to MCS, and correlated with clinical score.

276 Alterations due to MCS impact every gene ontology category queried, includi

277 t of VS/UWS patients, two of whom evolved to MCS.

278 on of prostaglandins after FLACS relative to MCS (WMD, 198.34; 95% CI, 129.99-266.69; P < 0.001).

279 ACS is more efficacious and safe relative to MCS.

280 Across all eyes, ReLACS was superior to MCS for reducing surgical time (MCS: 7.7 +/- 0.1 min vs

281 cult cases (n = 833), ReLACS was superior to MCS for: 1) being more likely to yield an improvement of

282 c mice, both pre- and post-wounding, topical MCS-01 application accelerated wound healing comparable

283 tient or while managing a patient undergoing MCS.

284 decipher the molecular mechanisms underlying MCS formation.

285 d data on consecutive patients who underwent MCS implantation after ECLS between January 2010 and Aug

286 Forty-one percent of hospitals did not use MCS.

287 istance; however, a unified system that uses MCSs to differentiate between multi drug resistance (MDR

288 ion of hospitalizations for MI with CS using MCS (MCS ratio) and in-hospital mortality were evaluated

289 d Nvj3 in this study) localize to ER-vacuole MCSs independently of established tether Nvj1.

290 re significantly more common in FLACS versus MCS (RR, 3.73; 95% CI, 1.50-9.25; P = 0.005).

291 ecutive eyes, of which 1580 were treated via MCS, and 1564 were treated via ReLACS at Uptown Surgical

292 identification of a caregiver to assist with MCS care.

293 of this study was to examine how living with MCS affects the quality of life (QoL) of patients and th

294 analyzed 48 306 patients undergoing PCI with MCS at 432 hospitals between January 2004 and December 2

295 ous coronary intervention (PCI) treated with MCS (Impella or intra-aortic balloon pump).

296 Among patients undergoing PCI treated with MCS, 4782 (9.9%) received Impella; its use increased ove

297 g among patients undergoing PCI treated with MCS, with marked variability in its use and associated o

298 nscriptome analysis from wounds treated with MCS-01 or placebo showed that MCS-01 significantly modul

299 Patient are living longer with MCSs for bridge to transplant (BTT) and destination ther

300 Sahel, we find that convective cores within MCSs are favored on the downstream side of dry patches >